Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan S Coates

Showing results (71-80 of 106) with videos related to

Pageof 11
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 12, 2008
Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trialDiana Crivellari, Zhuoxin Sun, Alan S Coates, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 2, 2011
Disease-related outcomes with long-term follow-up: an updated analysis of the intergroup exemestane studyJudith M Bliss, Lucy S Kilburn, Robert E Coleman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2005
Site of primary tumor has a prognostic role in operable breast cancer: the international breast cancer study group experienceMarco Colleoni, David Zahrieh, Richard D Gelber, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 20, 2008
Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study GroupGiuseppe Viale, Meredith M Regan, Eugenio Maiorano, et al.
Annals of Surgical Oncology|September 25, 2016
Poor Prognosis After Second Locoregional Recurrences in the CALOR TrialIrene L Wapnir, Shari Gelber, Stewart J Anderson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 4, 2007
Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98Alan S Coates, Aparna Keshaviah, Beat Thürlimann, et al.
Journal of the National Cancer Institute|March 8, 2012
CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trialMeredith M Regan, Brian Leyland-Jones, Mark Bouzyk, et al.
Cancer|December 8, 2020
Clinical behavior of recurrent hormone receptor-positive breast cancer by adjuvant endocrine therapy within the Breast International Group 1-98 clinical trialJose P Leone, Bernard F Cole, Meredith M Regan, et al.
The Lancet. Oncology|June 21, 2015
Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trialsJürg Bernhard, Weixiu Luo, Karin Ribi, et al.
Cancer|March 26, 2003
Decreased immunoreactivity for p27 protein in patients with early-stage breast carcinoma is correlated with HER-2/neu overexpression and with benefit from one course of perioperative chemotherapy in patients with negative lymph node status: results from International Breast Cancer Study Group Trial VVito J Spataro, Heather Litman, Giuseppe Viale, et al.
Pageof 11

Showing results (71-80 of 106) with videos related to

Sort By:
Pageof 11
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 12, 2008
Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trialDiana Crivellari, Zhuoxin Sun, Alan S Coates, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 2, 2011
Disease-related outcomes with long-term follow-up: an updated analysis of the intergroup exemestane studyJudith M Bliss, Lucy S Kilburn, Robert E Coleman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2005
Site of primary tumor has a prognostic role in operable breast cancer: the international breast cancer study group experienceMarco Colleoni, David Zahrieh, Richard D Gelber, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 20, 2008
Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study GroupGiuseppe Viale, Meredith M Regan, Eugenio Maiorano, et al.
Annals of Surgical Oncology|September 25, 2016
Poor Prognosis After Second Locoregional Recurrences in the CALOR TrialIrene L Wapnir, Shari Gelber, Stewart J Anderson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 4, 2007
Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98Alan S Coates, Aparna Keshaviah, Beat Thürlimann, et al.
Journal of the National Cancer Institute|March 8, 2012
CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trialMeredith M Regan, Brian Leyland-Jones, Mark Bouzyk, et al.
Cancer|December 8, 2020
Clinical behavior of recurrent hormone receptor-positive breast cancer by adjuvant endocrine therapy within the Breast International Group 1-98 clinical trialJose P Leone, Bernard F Cole, Meredith M Regan, et al.
The Lancet. Oncology|June 21, 2015
Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trialsJürg Bernhard, Weixiu Luo, Karin Ribi, et al.
Cancer|March 26, 2003
Decreased immunoreactivity for p27 protein in patients with early-stage breast carcinoma is correlated with HER-2/neu overexpression and with benefit from one course of perioperative chemotherapy in patients with negative lymph node status: results from International Breast Cancer Study Group Trial VVito J Spataro, Heather Litman, Giuseppe Viale, et al.
Pageof 11